The drug is based on antisense technology, which is a therapy for dramatically reducing disease-causing proteins. The study drug uniquely targets complement factor B, which is a protein found in the liver, blood and eyes, and a known risk factor for developing GA due to AMD. The study drug is designed to delay the progression of AMD by modulating or dampening complement factor B over-activity in the back of the eye.
A
A
Would you like to know more about the GOLDEN study?
